1.
              Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434438. 
                      Find this article online
                    
2.
              Charlton M (2004) Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2: 10481058.
        doi:
        10.1016/S1542-3565(04)00440-9.
       
                      Find this article online
                    
3.
              Hubscher SG (2006) Histological assessment of non-alcoholic fatty liver disease. Histopathology 49: 450465.
        doi:
        10.1111/j.1365-2559.2006.02416.x.
       
                      Find this article online
                    
4.
              Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK (2009) NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 104: 861867.
        doi:
        10.1038/ajg.2009.67.
       
                      Find this article online
                    
5.
              Bertrand JB, Lefevre H, Prevot S, Perlemuter G (2011) Nonalcoholic fatty liver disease in a severely obese adolescent. An arguable liver biopsy. Arch Pediatr 18: 6265. 
                      Find this article online
                    
6.
              Brookes MJ, Cooper BT (2007) Hypertension and fatty liver: guilty by association? J Hum Hypertens 21: 264270.
        doi:
        10.1038/sj.jhh.1002148.
       
                      Find this article online
                    
7.
              Fatani S, Itua I, Clark P, Wong C, Naderali EK (2011) The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage. Int J Gen Med 4: 211219. 
                      Find this article online
                    
8.
              Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, et al. (2010) From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 42: 320330.
        doi:
        10.1016/j.dld.2010.01.016.
       
                      Find this article online
                    
9.
              Day CP (2010) Genetic and environmental susceptibility to non-alcoholic fatty liver disease. Dig Dis 28: 255260.
        doi:
        10.1159/000282098.
       
                      Find this article online
                    
10.
              Merriman RB, Aouizerat BE, Bass NM (2006) Genetic influences in nonalcoholic fatty liver disease. J Clin Gastroenterol 40 Suppl 1S3033. 
                      Find this article online
                    
11.
              Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, et al. (2009) Heritability of nonalcoholic fatty liver disease. Gastroenterology 136: 15851592.
        doi:
        10.1053/j.gastro.2009.01.050.
       
                      Find this article online
                    
12.
              Li X, Meng Y, Wu P, Zhang Z, Yang X (2007) Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. Regul Pept 138: 1525.
        doi:
        10.1016/j.regpep.2006.07.011.
       
                      Find this article online
                    
13.
              Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, et al. (2001) Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34: 745750.
        doi:
        10.1053/jhep.2001.28231.
       
                      Find this article online
                    
14.
              Oakley F, Teoh V, Ching ASG, Bataller R, Colmenero J, et al. (2009) Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 136: 23342344. 
                      Find this article online
                    
15.
              Yoneda M, Hotta K, Nozaki Y, Endo H, Uchiyama T, et al. (2009) Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int 29: 10781085.
        doi:
        10.1111/j.1478-3231.2009.01988.x.
       
                      Find this article online
                    
16.
              Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Chayama K (2009) Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol 50: 12261235.
        doi:
        10.1016/j.jhep.2009.01.018.
       
                      Find this article online
                    
17.
              Zain SM, Mohamed R, Mahadeva S, Cheah PL, Rampal S, et al.. (2012) A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum Genet; doi:10.1007/s00439-012-1141-y 
18.
              Ruhl CE, Everhart JE (2005) Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 3: 12601268.
        doi:
        10.1016/S1542-3565(05)00743-3.
       
                      Find this article online
                    
19.
              Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA (2011) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53: 810820.
        doi:
        10.1002/hep.24127.
       
                      Find this article online
                    
20.
              Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 13131321.
        doi:
        10.1002/hep.20701.
       
                      Find this article online
                    
21.
              Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, et al. (2007) A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet 80: 11251137.
        doi:
        10.1086/518312.
       
                      Find this article online
                    
22.
              Chen GB, Xu Y, Xu HM, Li MD, Zhu J, et al. (2011) Practical and theoretical considerations in study design for detecting gene-gene interactions using MDR and GMDR approaches. PLoS One 6: e16981.
        doi:
        10.1371/journal.pone.0016981.
       
                      Find this article online
                    
23.
              Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57: 12. 
                      Find this article online
                    
24.
              Fujita K, Yoneda M, Wada K, Mawatari H, Takahashi H, et al. (2007) Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 52: 34553464.
        doi:
        10.1007/s10620-007-9741-4.
       
                      Find this article online
                    
25.
              Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, et al. (2007) Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45: 13751381.
        doi:
        10.1002/hep.21638.
       
                      Find this article online
                    
26.
              Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, et al. (2010) Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 51: 942952.
        doi:
        10.1002/hep.23419.
       
                      Find this article online
                    
27.
              Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, et al. (2004) Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40: 12221225.
        doi:
        10.1002/hep.20420.
       
                      Find this article online
                    
28.
              Hock SS (2007) Chinese Migration. The population of Malaysia. ISEAS Publishing. 
29.
              Periasamy M (2007) Indian Migration Into Malaya and Singapore During the British Period. Biblioasia. 
30.
              Hammer MF, Karafet TM, Park H, Omoto K, Harihara S, et al. (2006) Dual origins of the Japanese: common ground for hunter-gatherer and farmer Y chromosomes. J Hum Genet 51: 4758.
        doi:
        10.1007/s10038-005-0322-0.
       
                      Find this article online
                    
31.
              Omoto K, Saitou N (1997) Genetic origins of the Japanese: a partial support for the dual structure hypothesis. Am J Phys Anthropol 102: 437446. 
                      Find this article online
                    
32.
              Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, et al. (2004) Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 41: 751757.
        doi:
        10.1016/j.jhep.2004.07.010.
       
                      Find this article online
                    
33.
              Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, et al. (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37: 12861292.
        doi:
        10.1053/jhep.2003.50229.
       
                      Find this article online
                    
34.
              Abrams GA, Kunde SS, Lazenby AJ, Clements RH (2004) Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology 40: 475483.
        doi:
        10.1002/hep.20323.
       
                      Find this article online
                    
35.
              Dixon JB, Bhathal PS, O'Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121: 91100.
        doi:
        10.1053/gast.2001.25540.
       
                      Find this article online
                    
36.
              Lima ML, Mourao SC, Diniz MT, Leite VH (2005) Hepatic histopathology of patients with morbid obesity submitted to gastric bypass. Obes Surg 15: 661669. 
                      Find this article online
                    
37.
              Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, et al. (2005) Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 15: 310315.
        doi:
        10.1381/0960892053576820.
       
                      Find this article online
                    
38.
              Jou J, Choi SS, Diehl AM (2008) Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28: 370379.
        doi:
        10.1055/s-0028-1091981.
       
                      Find this article online
                    
39.
              Hoekstra M, Li Z, Kruijt JK, Van Eck M, Van Berkel TJ, et al. (2010) The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. J Hepatol 52: 244251.
        doi:
        10.1016/j.jhep.2009.11.004.
       
                      Find this article online
                    
40.
              Corey KE, Shah N, Misdraji J, Abu Dayyeh BK, Zheng H, et al. (2009) The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 29: 748753. 
                      Find this article online
                    